Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting

JAMA Cardiololgy

27 Settembre Set 2016 2 months ago
  • Zanobini M

Objective of this paper was to evaluate, in a prospective, multicenter clinical trial, performed at 15 European centers of cardiac surgery, the safety of preoperative use of ticagrelor with or without aspirin in 786 consecutive patients with acute coronary syndromes (ACS) undergoing isolated coronary artery bypass grafting (CABG) compared with aspirin alone.

In propensity score-matched analyses among patients with ACS undergoing CABG, the use of preoperative ticagrelor with or without aspirin compared with aspirin alone was associated with more platelet transfusion but similar degree of bleeding; in patients receiving ticagrelor 1 day before or up until surgery, there was an increased rate of severe bleeding.

Reference

  1. Gherli R, Mariscalco G, Dalén M, Onorati F, Perrotti A, Chocron S, Verhoye JP, Gulbins H, Reichart D, Svenarud P, Faggian G, Santarpino G, Fischlein T, Maselli D, Dominici C, Musumeci F, Rubino AS, Mignosa C, De Feo M, Bancone C, Gatti G, Maschietto L, Santini F, Nicolini F, Gherli T, Zanobini M, Kinnunen EM, Ruggieri VG, Rosato S, Biancari F. Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting. JAMA Cardiol 2016 Sep 21 [Epub ahead of print] Go to PubMed